Table 1.

Available “novel” agents for upfront treatment of CLL/SLL

Therapy	PFS at 2 y		PFS at 5 y		OS at 2 y
	%	Ref.	%	Ref.	%	Ref.
Ibrutinib	87; 95	15; 3,4	70	15	98	16
Acalabrutinib	87	6	TBD		95	6
Acalabrutinib and obinutuzumab	93	6	TBD		95	6
Venetoclax and obinutuzumab	88	2	TBD		91.8	2

Ref., reference number; TBD, to be determined.